首页> 美国政府科技报告 >Potential Radiosensitizing Antiviral and Anticancer Pyrimidine Nucleosides. Final Report, June 1, 1974--May 31, 1978
【24h】

Potential Radiosensitizing Antiviral and Anticancer Pyrimidine Nucleosides. Final Report, June 1, 1974--May 31, 1978

机译:潜在的放射增敏抗病毒和抗癌嘧啶核苷。最终报告,1974年6月1日 - 1978年5月31日

获取原文

摘要

The synthesis of a variety of novel nucleosides as potential antiviral, antineoplastic, and radiation sensitizing agents was investigated. The most significant accomplishment of this period was the development of 5-Iodo-5'-amino-2',5'-dideoxyuridine (AIU, AIdUrd) which is the first compound to require unequivocally, for antiviral activity, a unique activation by an enzyme (thymidine kinase) encoded by the Herpes virus genome. This unusual requirement for activation prevents toxicity to uninfected cells or tissues. The major conceptual contribution is that a non-toxic drug for established viral infections can indeed be developed. Although AIU is not a substrate for E. coli thymidine- or thymidylate kinase, it does bind to these enzymes and has a K/sub i/ of 240 mu M and 59 mu M respectively. Both enzymes are sensitized to uv radiations, and the concentrations required for 50 percent enhancement is roughly equivalent to their respective K/sub i/. Various other halogenated nucleoside analogs were prepared and evaluated for radiation sensitization potential. Mammalian enzymes appear to be less sensitive to uv radiations than bacterial enzymes. In an attempt to overcome this problem 5'-azido nucleoside analogs were prepared, but these were not effective. (ERA citation 04:027357)

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号